Synthego was founded in 2012 by Alex Pesch, Michael Dabrowski, and Paul Dabrowski. When asked about a potential IPO, CEO Dabrowski said that while "We think we can basically be ready for that anytime... From a publicity standpoint, from a people and teams standpoint, a financial capital needs standpoint, now we’ve decided to stay private." These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Synthego is a genome engineering company leveraging machine learning, automation, and gene editing to build platforms at scale. The company is a major developer of the tools which are used in CRISPR therapies, citing more than 1,000 peer-reviewed studies that have used its technology in at least one step. The company has raised more than $450 million in venture capital funding from investors including Perceptive Advisors LLC, SoftBank Vision Fund 2, Moore Strategic Ventures, Declaration Partners, Laurion Capital Management, and Logos Capital. Synthego did not release valuation information after a $200 million equity round in early 2022, but it is estimated at between $800 million and $1.2 billion.
Synthego does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for Synthego will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 2/17/2022 | Series E | $1.3B | $XXX.XX | $XXX.XX |
| 8/26/2020 | Series D | $486.63MM | $XXX.XX | $XXX.XX |
| 10/23/2018 | Series C | $381.27MM | $XXX.XX | $XXX.XX |
| 1/4/2017 | Series B and B-1 | $115.78MM | $XXX.XX | $XXX.XX |
| 7/5/2013 | Series A | $33.21MM | $XXX.XX | $XXX.XX |
Synthego is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Synthego pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Synthego is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
